^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    12h
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=66, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> May 2028 | Trial primary completion date: Nov 2027 --> May 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
    14h
    VALO-001: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Valo Therapeutics Oy | Active, not recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Oct 2026 --> Apr 2027
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • MAGEA3 (MAGE Family Member A3)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1
    18h
    EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=366, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Sep 2032 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin
    23h
    ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=4994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    CELLSEARCH®
    |
    Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    23h
    REDUCy: Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies (clinicaltrials.gov)
    P3, N=180, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Sep 2029 --> Jun 2030 | Initiation date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2029 --> Jun 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cyclophosphamide
    23h
    Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (clinicaltrials.gov)
    P3, N=550, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    23h
    BEACON: Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (clinicaltrials.gov)
    P2, N=225, Completed, University of Birmingham | Active, not recruiting --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • temozolomide • cyclophosphamide • irinotecan • topotecan • Qarziba (dinutuximab beta)
    1d
    Novel Fusion Gene Transcripts and Targetable Mutations in High-Risk B-ALL With Exceptional Response to Venetoclax-Based Therapy. (PubMed, Genes Chromosomes Cancer)
    The patient received induction therapy with a modified COP regimen (cyclophosphamide, vindesine, dexamethasone) combined with the BCL2 inhibitor venetoclax, achieving a rapid and sustained complete remission. This case suggests that integrating deep genomic analysis can help identify potentially actionable therapeutic targets and provides preliminary clinical evidence supporting the efficacy of modified COP plus venetoclax in high-risk B-ALL with similar molecular features, highlighting a promising precision medicine strategy.
    Journal • IO biomarker
    |
    BCL6 (B-cell CLL/lymphoma 6) • CREBBP (CREB binding protein) • ARID1B (AT-Rich Interaction Domain 1B) • MAN1A1 (Mannosidase Alpha Class 1A Member 1) • GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)
    |
    Venclexta (venetoclax) • cyclophosphamide • vindesine
    1d
    Orbital alveolar rhabdomyosarcoma with central nervous system invasion in adult: A case report. (PubMed, Surg Neurol Int)
    The patient received adjuvant radiotherapy and chemotherapy with irinotecan, vincristine, actinomycin D, ifosfamide, cyclophosphamide, and vinorelbine. The lack of guidelines for the adult population implies the need to adapt therapeutic strategies from pediatric protocols. Comprehensive diagnosis integrating imaging, histopathology, and molecular testing is essential for accurate classification and treatment planning.
    Journal
    |
    PAX3 (Paired Box 3)
    |
    cyclophosphamide • ifosfamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin
    1d
    ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, National Hospital Organization Nagoya Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • cyclophosphamide • epirubicin • vincristine • daunorubicin • mercaptopurine
    2d
    Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response. (PubMed, Blood Res)
    CD79B expression was independently associated with a poor response to R-CHOP therapy in non-GCB DLBCL. The positive association between TERT and LC3 suggests the presence of additional metabolic adaptation mechanisms supporting tumor survival.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase) • CD79B (CD79b Molecule) • MAP1LC3B (Microtubule Associated Protein 1 Light Chain 3 Beta)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone
    2d
    Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IFNG (Interferon, gamma)
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan